You are here: Industry Insights > DoD

News List

DoD Not Protecting Service Members From Toxic 'Forever Chemicals': Audit drugs
July 29, 2021
The U.S. Department of Defense (DoD) is not doing enough to guard service members against exposure to so-called "forever chemicals" associated with a range of health problems, the department's inspector general said Tuesday.
Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment worldpharmanews
March 22, 2021
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
AstraZeneca to supply 500,000 doses of Covid-19 antibody to the US pharmaceutical-technology
March 18, 2021
AstraZeneca (AZ) has signed an agreement with the US Department of Health and Human Services (HHS) and the Department of Defense (DoD) for the supply of up to 500,000 additional doses of its Covid-19 antibody treatment for $205m.
Just, Evotec Expand mAbs Manufacturing Contract with DOD contractpharma
February 03, 2021
Evotec SE announced that the U.S. Department of Defense (DOD) awarded its Seattle, WA-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (mAbs) for use in the development of a ...
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients prnewswire
February 01, 2021
Rigel Pharmaceuticals, Inc. announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel's ongoing Phase 3 ...
Humanetics receives US DoD funding for Covid-19 drug development pharmaceutical-technology
January 28, 2021
Humanetics has received funding from the US Department of Defense (DoD) to carry out a series of studies with its novel drug candidate, BIO 300, for Covid-19.
CONTINUUS Awarded $69.3M DoD Grant contractpharma
January 25, 2021
CONTINUUS Pharmaceuticals Inc. received a $69.3 million U.S. government contract to facilitate domestic production of three vital medicines used to treat critically ill patients, including COVID-19.
Spinogenix Announces Grant by DOD to Advance ALS Drug Candidate americanpharmaceuticalreview
January 12, 2021
Spinogenix will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s (DOD) ...
DOD Awards Ology Vaccine Manufacturing Contract contractpharma
October 29, 2020
CDMO to manufacture and test novel live attenuated tularemia vaccine candidate.
DoD Selects Pharm-Olam to Support to Operation Warp Speed Vax Trials contractpharma
September 24, 2020
To support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed.

Previous page 1 2 Next page